Physician profile
Caitlin E Smith
NPI 1629525167
$4,149.88
in general payments reported to CMS, 2019-2025
26 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $815 · 2022: $1,001 · 2023: $1,217 · 2024: $782 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,163.74 |
| Education | $169.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $909.62 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $384.53 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $373.77 | 2021-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $301.05 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.60 | 2021-2024 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Pfizer INC. | $276.98 | 2021-2024 | |
| Novo Nordisk INC | $254.07 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $172.40 | 2021-2025 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $123.12 | 2021-2025 | Farxiga, Breztri |
| E.R. Squibb & Sons, L.L.C. | $121.22 | 2021-2024 | Camzyos |
| Merck Sharp & Dohme LLC | $115.58 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $110.19 | 2022-2023 | Contrave, Nexletol, Onzetra Xsail |
| Novartis Pharmaceuticals Corporation | $99.22 | 2021-2023 | |
| Exact Sciences Corporation | $81.68 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $71.74 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $69.34 | 2021-2023 | Xarelto |
| Amgen INC. | $61.39 | 2021-2023 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $59.44 | 2023-2025 | |
| Mylan Specialty L.P. | $56.03 | 2022 | |
| Sanofi-Aventis U.S. LLC | $50.20 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $35.20 | 2022 | |
| Grifols USA, LLC | $33.58 | 2021 | |
| Esperion Therapeutics, INC. | $32.93 | 2021-2023 | Nexletol |
| Bausch Health US, LLC | $28.37 | 2021-2022 | |
| Optinose US, INC. | $17.75 | 2022 | |
| Eisai INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.